RESUMEN
Objective:To evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of the patients with primary hyperlipidemia in China.Methods:The related literatures in CNKI,VIP,Wanfang medicine network,PubMed/MEDLINE,CBM and Chinese dissertations full text database were retrievaled by computer from the establishment time of database to December 31,2015. Two researchers according to the inclusion and exclusion criteria independently selected the studies and extracted the data and assessed the quality of the literatures.The Revman 5.0 software was used to perform Meta analysis of all effect indicators in various groups.Results:A total of 7 randomized controlled trial (RCT)were included,and there was no significant abnormality in bias evaluation. 8 weeks after treatment, the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C)and high density lipoprotein cholesterol (HDL-C)levels of the patients in 5 mg rosuvastain group and 10 mg atorvastatin group had no significant differences between before and after treatment (P >0.05);the HDL-C levels of the patients in 10 mg rosuvastatin group and 10 mg atorvastatin group had significant differences between before and after treatment (P 0.05);the TG,TC,LDL-C and HDL-C levels of the patients in 5 mg and 10 mg rosuvastatin groups had no significant differences between before and after treatment (P > 0.05).12 weeks after treatment,there were no significant differences in the TC and LDL-C levels between 10 mg rosuvastatin group and 10 mg atorvastatin group (P >0.05),but there were significant differences in the TG and HDL-C levels (P 0.05).Conclusion:5 mg rosuvastatin and 10 mg atorvastatin in the treatment of the patients with primary hypercholesterolemia have similar lipid-lowering effect;with the the increase of the treatment time and the dose,10 mg rosuvastatin can obviously reduce the TG level and increase the HDL-C level of the patients,and the incidence of adverse reactions of two kinds of doses of rosuvastatin has no obvious difference.
RESUMEN
Objective To observe the effect of Rosuvastatin on apolipoprotein A1 (Apo A1),apolipoprotein B(Apo B) and Apo B/Apo A1 patients with acute coronary syndrome.Methods One hundred and fifty hospitalized patients with acute coronary syndrome were randomly divided into three groups,A group (Rosuvastatain,5 mg/d),B group (Rosuvastatain,10 mg/d),and C group (Simvastatin,20 mg/d).Before and at 4,8 weeks after treatments tested the three groups' cholesterol (TC),glycerin(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol (LDL-C),Apo A1,Apo B.Compare the blood lipids aforementioned before and after treatments in three groups.Results (1) After treatments for 4 weeks,TC,LDLC in three groups are significant lower than before (P ＜ 0.05).After treatments for 8 weeks,TC,LDL-C,Apo B,Apo B/Apo A1 of three groups are lower than before and HDL-C 、Apo A1 is higher than before (P ＜ 0.05).(2)After treatments for 8 weeks,comparing to A and C groups,TC,LDL-C,Apo B,Apo B/Apo A1 in B group were lower while HDL-C、Apo A1 were higher (P ＜ 0.05).(3)The incidences of liver damage has no significant differences among three groups (x2 =1.25,P ＞ 0.05).Conclusion Effects of 10 mg/d rosuvastatain were better than 5 mg/d rosuvastatain and 20 mg/d simvastatin in increasing Apo A1 and decreasing Apo B,Apo B/Apo A1,and then effectively control of ACS.